Form 8-K - Current report:
SEC Accession No. 0000950170-25-083866
Filing Date
2025-06-09
Accepted
2025-06-09 17:25:47
Documents
11
Period of Report
2025-06-03
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20250603.htm   iXBRL 8-K 48835
2 EX-16.1 lctx-ex16_1.htm EX-16.1 4768
  Complete submission text file 0000950170-25-083866.txt   157546

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250603.xsd EX-101.SCH 23883
13 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250603_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 251035155
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)